Keywords
Adjunctive therapy
Focal seizure
Epilepsy
Mexico
Categories
How to Cite
Abstract
Introduction: To evaluate, in a post-hoc subgroup analysis, the efficacy, safety, and tolerability of brivaracetam (BRV) as an adjunctive treatment compared with placebo in patients with uncontrolled focal (partial-onset) seizures recruited in Mexico. Patients and Methods: Seizure outcomes data were pooled from two phase III trials, NCT01339559 (N01379) and NCT00150800 (N01199). The pooled safety and efficacy data from these trials for the Mexican population were evaluated as a descriptive analysis of these core trials. Results: Of 179 Mexican patients who were evaluated, 67.5% completed the two trials, including a long-term follow-up that lasted more than 4 years. Of the patients who completed, 27 (96.3%) had been treated with a BRV dose of 20 mg/day, 26 (88.5%) with 50 mg/day, 21 (81.0%) with 100 mg/day, and 21 (85.7%) with 200 mg/day. After 2 years’ treatment, 81% of patients had responded to treatment at a dose > 50 mg/day. In the safety analysis, only five patients discontinued because of treatment, and 26 patients had developed serious adverse events overall in the two trials. Conclusion: Adjunctive treatment with BRV in adults with focal seizures was effective and generally well tolerated when administered long term.
References
Toledo M, Whitesides J, Schiemann J, et al. Safety, tolerability, and seizure control during long-term treatment with adjunctive brivaracetam for partial-onset seizures. Epilepsia 2016:57:1139–1151.
UCB, Brussels, Belgium. Briviact® EU Prescribing Information. 2016. Available at:http://www.ema.europa.eu/docs/en_GB/document_library/ EPAR_-_Product_Information/human/003898/WC50020020 6.pdf. Accessed June 4, 2018.
UCB, Brussels, Belgium. Briviact® US Prescribing Information. 2018. Available at:https://www.briviact.com/briviact-PI.pdf. Accessed June 4, 2018.
Asadi-Pooya AA, Sperling MR, Chung S, et al. Efficacy and tolerability of adjunctive brivaracetam in patients with prior antiepileptic drug exposure: a post-hoc study. Epilepsy Res 2017;137:70–75.
Elinor Ben-Menachem, et al. Eficacia y seguridad de brivaracetam para crisis de inicio
parcial en tres estudios clínicos agrupados, 2016.
French JA, Costantini C, Brodsky A, et al. Adjunctive brivaracetam for refractory partial-onset seizures: a randomized, controlled trial. Neurology 2010;75;519–525.
Kasteleijn-Nolst Trenité DG, Genton P, Parain D, et al. Evaluation of brivaracetam, a novel SV2A ligand, in the photosensitivity model. Neurology 2007;69;1027–1034.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright (c) 2025 Fernando Guzman-Reyes, Jorge Villarreal-Careaga, John Whitesides, Iván González-Gómez